Trevi Therapeutics, Inc. (TRVI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
195 Church Street
New Haven, CT 06510
United States of America (the)
Phone
203 304 2499
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
May 07, 2019
| Name | Title | Pay | Year Born |
| Jennifer L. Good | Co-Founder, Chief Executive Officer, President & Director | 976,632 | 1965 |
| Farrell Simon | Chief Commercial Officer | 530,567 | N/A |
| Thomas R. Sciascia | Co-Founder & Chief Scientific Officer | 551,426 | 1953 |
| James V. Cassella | Chief Development Officer | 694,770 | 1955 |
| David C. Hastings | Chief Financial Officer & Principal Financial Officer | 0 | 1961 |
| Katherine Takaki | Senior Vice President of Global Regulatory Affairs | 0 | N/A |
| Katie McManus | Communications Manager | 0 | N/A |
| Christopher Galletta | Controller & Chief Accounting Officer | 0 | 1978 |
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.